Lowest-Rated StocksLowest-RatedNASDAQ:REPL Replimune Group (REPL) Stock Price, News & Analysis $5.01 -0.21 (-3.93%) As of 12:14 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Replimune Group Stock (NASDAQ:REPL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Replimune Group alerts:Sign Up Key Stats Today's Range$4.97▼$5.2550-Day Range$1.70▼$8.5452-Week Range$1.50▼$13.24Volume1.37 million shsAverage Volume4.35 million shsMarket Capitalization$414.09 millionP/E RatioN/ADividend YieldN/APrice Target$4.75Consensus RatingReduce Company Overview Replimune Group, Inc. is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses. Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation. The company’s pipeline also includes RP2, RP3 and RP4, each engineered with distinct cytokine or co‐stimulatory transgenes to address different tumor types and immune environments. Clinical studies to date have evaluated these candidates as monotherapies and in combination with checkpoint inhibitors, with initial data reported in melanoma, cutaneous squamous cell carcinoma and other solid tumors. Founded in 2015 and headquartered in Woburn, Massachusetts, Replimune designs and executes clinical trials across North America and Europe. The company’s research and manufacturing infrastructure supports rapid development and scalable production of its viral immunotherapies. Replimune maintains collaborations with academic institutions and clinical research organizations to advance its programs through late-stage studies. Replimune is led by an experienced management team and board of directors with deep expertise in oncology drug development, virology and regulatory affairs. The company’s leadership draws on years of precedent in advancing innovative cancer treatments from early discovery into pivotal clinical trials.AI Generated. May Contain Errors. Read More Replimune Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreREPL MarketRank™: Replimune Group scored higher than 26% of companies evaluated by MarketBeat, and ranked 762nd out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.8 / 5Analyst RatingReduce Consensus RatingReplimune Group has received a consensus rating of Reduce. The company's average rating score is 1.60, and is based on no strong buy ratings, no buy ratings, 6 hold ratings, and 4 sell ratings.Downside RiskReplimune Group has a consensus price target of $4.75, representing about 5.3% downside from its current price of $5.02.Amount of Analyst CoverageReplimune Group has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Replimune Group's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Replimune Group are expected to grow in the coming year, from ($3.39) to ($2.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Replimune Group's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted27.03% of the float of Replimune Group has been sold short.Short Interest Ratio / Days to CoverReplimune Group has a short interest ratio ("days to cover") of 2.64, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Replimune Group has recently increased by 14.83%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 5 news articles for Replimune Group this week, compared to 8 articles on an average week.Search InterestOnly 20 people have searched for REPL on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.MarketBeat Follows8 people have added Replimune Group to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $52,065.00 in company stock.Percentage Held by Insiders5.20% of the stock of Replimune Group is held by insiders.Percentage Held by Institutions92.53% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Replimune Group's insider trading history. Receive REPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. REPL Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPLMay 21 at 4:40 PM | prnewswire.comReplimune Group (REPL) Expected to Announce Earnings on ThursdayMay 21 at 1:26 AM | americanbankingnews.comThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.May 22 at 1:00 AM | Behind the Markets (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPLMay 19 at 6:07 PM | globenewswire.comREPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law FirmMay 17, 2026 | globenewswire.comReplimune Group, Inc. (NASDAQ:REPL) Given Consensus Recommendation of "Reduce" by AnalystsMay 16, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPLMay 14, 2026 | prnewswire.comReplimune: Perhaps The FDA Shakeup Will Get A Mulligan For RP1May 13, 2026 | seekingalpha.comSee More Headlines REPL Stock Analysis - Frequently Asked Questions How have REPL shares performed this year? Replimune Group's stock was trading at $9.72 on January 1st, 2026. Since then, REPL shares have decreased by 47.8% and is now trading at $5.0740. How were Replimune Group's earnings last quarter? Replimune Group, Inc. (NASDAQ:REPL) issued its quarterly earnings data on Thursday, November, 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.87) by $0.03. When did Replimune Group IPO? Replimune Group (REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. Who are Replimune Group's major shareholders? Top institutional investors of Replimune Group include Dimensional Fund Advisors LP (1.38%), EcoR1 Capital LLC (1.21%), Candriam S.C.A. (0.48%) and Renaissance Technologies LLC (0.46%). Insiders that own company stock include Robert Coffin, Philip Astley-Sparke, Colin Love, Sushil Patel, Pamela Esposito, Christopher Sarchi, Konstantinos Xynos, Tanya Lewis, Emily Luisa Hill, Andrew Schwendenman and Kapil Dhingra. View institutional ownership trends. How do I buy shares of Replimune Group? Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Replimune Group investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Home Depot (HD). Company Calendar Last Earnings11/06/2025Today5/22/2026Next Earnings (Estimated)5/28/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, REPL's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:REPL CIK1737953 Webwww.replimune.com Phone(781) 222-9600FaxN/AEmployees210Year Founded2015Price Target and Rating Average Price Target for Replimune Group$4.75 High Price Target$12.00 Low Price Target$2.00 Potential Upside/Downside-4.9%Consensus RatingReduce Rating Score (0-4)1.60 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($3.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$247.30 million Net MarginsN/A Pretax MarginN/A Return on Equity-102.69% Return on Assets-72.22% Debt Debt-to-Equity Ratio0.33 Current Ratio5.60 Quick Ratio5.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.40 per share Price / Book0.93Miscellaneous Outstanding Shares82,570,000Free Float78,279,000Market Cap$412.44 million OptionableOptionable Beta0.12 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:REPL) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredMaybe the Greatest Strategy of the DecadeNate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
